Page last updated: 2024-10-31

nafronyl and Scleroderma, Systemic

nafronyl has been researched along with Scleroderma, Systemic in 2 studies

Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.

Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gaylarde, PM2
Tan, OT2
Sarkany, I2

Other Studies

2 other studies available for nafronyl and Scleroderma, Systemic

ArticleYear
Blood flow changes with naftidrofuryl in systemic sclerosis and Raynaud's phenomenon.
    The British journal of dermatology, 1980, Volume: 102, Issue:1

    Topics: Adult; Aged; Body Temperature Regulation; Female; Fingers; Forearm; Furans; Humans; Leg; Male; Middl

1980
Effect of naftidrofuryl oxalate (praxilene) on peripheral circulation measured by calorimetry.
    The Australasian journal of dermatology, 1978, Volume: 19, Issue:2

    Topics: Adult; Body Temperature; Calorimetry; Female; Fingers; Furans; Humans; Injections, Intravenous; Male

1978